PubMed Health⌕ Search

Biomedical subjects

L C Reis

Publications and source records attributed to L C Reis.

At least 37 records · Page 2Linked to original sources

Brain serotoninergic stimulation reduces the water intake induced by systemic and central beta-adrenergic administration.

1. This study was undertaken to determine if the stimulation of central serotoninergic receptors affects the thirst-inducing action of systemically or intracerebroventricularly (icv) injected isoproterenol. 2. Male Wistar rats weighing 220-300 g were used in groups of 10-14 animals each. Normally hydrated rats implanted with a delay cannula into the third ventricle were injected icv with the 5HT1C/5HT2 agonist MK212 (50 nmol/2 microliters) prior to administration of isoproterenol sc (330 micrograms/kg body weight) or icv (10 and 25 and 50 micrograms/2 microliters). 3. Icv injections of MK212 reduced the water intake induced by isoproterenol injected systemically (56%) and by the two lowest doses of isoproterenol injected icv (76 and 86%, respectively). 4. The results suggest that the central serotoninergic system modulates the central beta-adrenergic system involved in water intake. 5. Taken together with previous results showing that the activation of 5HT1C/5HT2 receptors promotes a reduction of the dipsogenic response evoked by water deprivation or by icv injection of angiotensin II or carbachol, the present data suggest that the central serotoninergic system plays a ubiquitous role in the modulation of water intake behavior.

Adrenergic beta-Agonists↗

Lesions of the hypothalamus and pituitary inhibit volume-expansion-induced release of atrial natriuretic peptide.

Expansion of the blood volume causes a release of atrial natriuretic peptide (ANP) that is believed to be important in induction of the subsequent natriuresis and diuresis which, in turn, acts to reduce the increase in blood volume. Since stimulation of the anteroventral portion of the third cerebral ventricle (AV3V) induced a rapid elevation of plasma ANP, whereas lesions of the AV3V were followed by a marked decline in plasma concentration of the peptide, we hypothesized that release of ANP from the brain ANP neuronal system might be important to the control of plasma ANP. The perikarya of the ANP-containing neurons are densely distributed in the AV3V and their axons project to the median eminence and neural lobe. To test the hypothesis that these neurons are involved in volume-expansion-induced ANP release, by using electrolysis we destroyed the AV3V, the site of the perikarya, in male rats. Other lesions were made in the median eminence and posterior pituitary, sites of termination of the axons of these neurons, and also hypophysectomy was performed in other animals. In conscious freely moving animals, volume expansion and stimulation of postulated sodium receptors in the hypothalamus were induced by injection of hypertonic NaCl solution [0.5 or 0.3 M NaCl; 2 ml/100 g (body weight)]. Volume expansion alone was induced with the same volume of an isotonic solution (NaCl or glucose). In the sham-operated rats, volume expansion with hypertonic or isotonic solutions caused equivalent rapid increases in plasma ANP that peaked at 5 min and returned nearly to control values by 15 min. Lesions caused a decrease in the initial levels of plasma ANP on comparison with values from the sham-operated rats, and each type of lesion induced a highly significant suppression of the response to volume expansion on testing 1-5 days after lesions were made. Because a common denominator of the lesions was elimination of the brain ANP neuronal system, these results suggest that the brain ANP plays an important role in the mediation of the release of ANP that occurs after volume expansion. Since the content of ANP in this system is much less than that in the atria, there must be a remarkable increase in synthesis and release of brain ANP associated with this stimulus. It is also possible that blockade of volume-expansion-induced release of other neurohypophyseal hormones, such as endothelin, may block release of ANP from atrial myocytes. It is probable that volume expansion detected by stretch of atrial and carotid-aortic baroreceptors causes afferent input to the brain ANP system, thereby causing increased release of the peptide from the median eminence and neural lobe. Our results emphasize the importance of brain ANP to the control of ANP release to the blood.

Animals↗

Participation of the median raphe nucleus and central serotoninergic pathways in the control of water electrolyte excretion.

1. The role of the median raphe nucleus (MRN) and of increased central serotonin (5HT) synthesis/release in the mediation of Na+ excretion (UNaV) and K+ excretion (UKV) and of urine output (UV) was evaluated for 120 min. 2. Male Wistar rats weighing 220-280 g were used in each group of 12-13 animals. The rats implanted with a cannula in the MRN were injected with saline (0.5 microliters) or with 5.0 and 15.0 ng/0.5 microliters kainic acid (KA), an excitatory amino acid (EAA). Another group of rats was injected ip with 200 mg/kg saline or tryptophan, the initial precursor of 5HT synthesis. 3. Injection of both kainic acid and tryptophan led to increased Na+ excretion, but the magnitude and time course were different for each treatment. 4. Both KA doses were effective in increasing UNaV (0.61 +/- 0.08, mean +/- SEM, and 0.95 +/- 0.19 microEq/min, respectively, vs 0.27 +/- 0.04 microEq/min for saline at 60 min). The effect on UKV was statistically significant with the 15.0 ng dose (0.44 +/- 0.05 microEq/min vs 0.25 +/- 0.03 microEq/min for saline) at 20 min. 5. Tryptophan administration caused an initial gradual increase in UNaV which became steady and significant after 60 min (1.02 +/- 0.15 microEq/min vs 0.36 +/- 0.06 microEq/min for saline), as well as an increase in UKV (0.58 +/- 0.06 microEq/min vs 0.26 +/- 0.04 microEq/min for saline) at 60 min and throughout the remainder of the observation period. 6. KA-induced MRN stimulation and systemic tryptophan overload significantly increased UV at 60, 80 and 100 min (30 to 97% above control values).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Effect of central administration of serotoninergic agonists on electrolyte excretion control.

1. The participation of different central serotoninergic (5HT) receptors in the mediation of Na+ excretion (UNaV), K+ excretion (UKV) and urine output (UV) was evaluated. 2. Male Wistar rats weighing 220-280 g were used in each group of 9-18 animals. The rats were injected intracerebroventricularly (icv) with the 5HT agonists MK212 (1.5, 15.0 and 30.0 micrograms), 8-OH-DPAT (5.0 and 15.0 micrograms), 5HT (2.5, 12.5 and 25.0 micrograms) and DOI (10.0 and 25.0 micrograms). 3. At the lowest MK212 dose, UNaV was significantly reduced (0.18 +/- 0.04 microEq/min vs 0.35 +/- 0.04 microEq/min for saline) at 20 min. At the highest dose, MK212 provoked a significant increase in UNaV (0.60 +/- 0.06 microEq/min vs 0.34 +/- 0.03 microEq/min for saline) at 40 min. UKV values were significantly modified only at the 1.5-micrograms dose (0.18 +/- 0.04 microEq/min vs 0.35 +/- 0.04 microEq/min for saline) at 20 min. 4. Icv injection of 8-OH-DPAT provoked a significant reduction in UNaV (0.16 +/- 0.05 microEq/min vs 0.35 +/- 0.03 microEq/min for saline) and UKV (0.15 +/- 0.05 microEq/min vs 0.34 +/- 0.02 microEq/min for saline) at 40 min both doses. 5. Icv injection of 5HT at the highest dose provoked a significant increase in UNaV (0.92 +/- 0.10 microEq/min vs 0.33 +/- 0.04 microEq/min for saline) and in UKV (0.55 +/- 0.08 microEq/min vs 0.24 +/- 0.07 microEq/min for saline) at 40 min. 6. Icv administration of DOI caused a natriuretic response (0.69 +/- 0.12 microEq/min vs 0.31 +/- 0.04 microEq/min for saline) at 40 min, with no significant effect on UKV.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Drinking behavior in thyroidectomized rats: effects of central cholinergic stimulation and of water deprivation.

Normally hydrated thyroidectomized (TX) rats stimulated intracerebroventricularly with carbachol and dehydrated TX rats drank significantly smaller volumes of water than their respective controls. This suggests lower central sensitivity to thirst and to drinking behavior induced by both cholinergic activation and extracellular fluid depletion. Dehydrated TX rats excreted a significantly larger urinary volume than the controls, suggesting the existence of changes in the renal mechanisms of water retention. Such changes could be related to a reduction in vasopressin binding sites.

Animals↗

Thyroidectomy reduces stress-induced prolactin secretion in rats. Participation of brain serotonergic systems.

Plasma prolactin levels were measured in thyroidectomized and sham-operated rats under immobilization stress. Thyroidectomy significantly reduced prolactin secretion during stress. The pretreatment of thyroidectomized rats with 6-chloro-2-[1-piperazinyl]- pyrazine (MK 212), a serotonin agonist that easily penetrates the blood-brain barrier, reversed the reduction in stress-induced prolactin release in the thyroidectomized group.

Animals↗

Central serotonergic modulation of drinking behavior induced by water deprivation: effect of a serotonergic agonist (MK-212) administered intracerebroventricularly.

The present study was carried out to evaluate the participation of the serotonergic system (5-HT) in the modulation of the drinking response induced by water deprivation. Male Wistar rats implanted with a cannula in the 3rd ventricle were injected with the 5-HT1C/5-HT2 agonist 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) at doses of 0.5, 5, 25, 50 and 125 nmol/2 microliters. MK-212 induced a significant reduction (P less than or equal to 0.05) in water intake over a period of 300 min. This result indicates that the central 5-HT system plays an important role, probably at the level of the periventricular hypothalamus, in the modulation of drinking behavior induced by water deprivation.

Animals↗

Central serotonergic modulation of drinking behavior induced by angiotensin II and carbachol in normally hydrated rats: effect of intracerebroventricular injection of MK-212.

The objective of the present study was to evaluate the role of the central serotonergic (5-HT) system in the modulation of drinking behavior induced by angiotensin II (Ang II) and carbachol. Male Wistar rats implanted with a delay cannula in the 3rd ventricle were injected with the 5-HT1C/5-HT2 agonist 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) (50 nmol/2 microliters) before receiving an intracerebroventricular (icv) injection of Ang II or carbachol (100 ng/2 microliters). MK-212 induced a significant reduction in the drinking response evoked by Ang II or carbachol which was more marked in the case of the cholinergic agonist. The results obtained suggest that thirst and water intake produced by angiotensinergic or cholinergic activation are modulated by the action of 5-HT, possibly at the level of the periventricular hypothalamus.

Angiotensin II↗

Participation of the serotonergic system in the regulation of water and electrolyte balance.

To determine the possible participation of the serotonergic (5-HT) system in the regulation of water and electrolyte balance, rats were submitted to two sessions of water overloading and the 5-HT agonist MK 212 was administered intracerebroventricularly (icv) in 1.0 microliters 20 min after the second session. Urine volume and sodium and potassium excretion were then measured over a period of 120 min. Microinjection of MK-212 (1 micrograms/animal) caused a significant reduction (24 to 57%; mean, 43%) in natriuresis throughout the experimental period, and the administration of 10 micrograms/animal caused a 26-41% reduction (mean, 33%) in kaliuresis. At 20 micrograms/animal, MK-212 did not change any of the parameters investigated. No significant change in urine volume was detected after any of the treatments used.

Animals↗

Cation transport by pancreatic beta-cells: effect of 4-aminopyridine on 86Rb+ and 45Ca2+ fluxes.

The effects of 4-aminopyridine (4-AP) on insulin release, glucose oxidation and 86Rb+ and 45Ca2+ fluxes of rat isolated islets were studied. 4-AP (0.1 and 1.0 mM) did not alter the 86Rb+ fractional efflux. However, 10 mM 4-AP significantly increased the 86Rb+ fractional efflux. 10 mM 4-AP also reduced the insulin release from islets incubated over 90 min in the presence of both 6 and 16.7 mM glucose and from perifused islet in the presence of 16.7 mM glucose. 4-AP (10 mM) only transiently increased the insulin release and the 45Ca2+ fractional efflux in the presence of 6 mM glucose. The 45Ca2+ fractional efflux was not changed when the islets were perifused at higher glucose concentration. At zero, 6 or 16.7 mM glucose, 4-AP (10 mM) significantly increased the 45Ca2+ net uptake by islets incubated for 90 min. 10 mM 4-AP significantly reduced the glucose oxidation of islets incubated for 120 min in the presence of 16.7 mM glucose. The effects of 10 mM 4-AP on the dynamics of insulin release and 86Rb+ fractional efflux were poorly reversible. In conclusion, 4-AP, at concentrations that did not alter the glucose metabolism, (0.1 and 1 mM), failed to affect the K+ permeability in beta-cells as judged by the measurements of 86Rb+ fractional efflux. At higher concentrations (10 mM) 4-AP increased 86Rb+ efflux, decreased glucose metabolism and reduced insulin release.

4-Aminopyridine↗

Thiopental inhibits K+ permeability of rat and mouse pancreatic beta-cells.

The effects of thiopental on the insulin release and 86Rb efflux from isolated rat islets and on parameters of the electrical activity of single beta-cells of mice were studied. Thiopental 0.2 and 1.0 mM increased by 16.6 and 33.3%, respectively, the insulin release induced by 6.0 mM glucose. Thiopental reduced the 86Rb efflux rate in both 0 and 6.0 mM glucose, but had only a slight effect in 16.7 mM glucose. Menadione (20 microM) did not block the inhibitory effect of thiopental on 86Rb efflux. Thiopental induced a reversible membrane depolarization in a dose-dependent manner (0.2-1.0 mM). It also induced electrical activity at a subthreshold glucose concentration and continuous spiking in presence of 11.1 mM glucose. In the presence of 2,4-dinitrophenol (20 microM) this continuous spiking was changed to an oscillatory activity similar to that induced by 11.1 mM glucose. Thiopental (0.5 mM) induced an increase in input resistance of 12.7, 17.9 and 16.0% in 0, 5.6 and 11.1 mM glucose, respectively. The thiopental-induced changes in insulin secretion, 86Rb efflux and electrical parameters indicate that K+ permeability was affected in both rat and mouse beta-cells. Our results suggest that thiopental is a direct inhibitor of the glucose-sensitive K+ permeability in the beta-cell.

Animals↗

Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.

We compared the effects of high and low dosages of antithyroid drugs in 113 patients with Graves' hyperthyroidism. The patients were randomly divided into 2 groups. In group A, 65 patients received either methimazole (MMI): 60 +/- 14.5 mg/day (mean +/- SD); range 40-100 mg/day, or propylthiouracil (PTU): 693 +/- 173 mg/day; range 500-1200 mg/day. These high doses were maintained throughout treatment with later addition of 50-75 micrograms T3 daily. Forty eight patients (group B) were treated with lower doses of MMI or PTU without thyroid hormone addition. The maintenance dose of MMI was 13.6 +/- 7 mg/day (range 5-25 mg/day) and that of PTU was 180 +/- 58 mg/day (range 100-300 mg/day). The treatment period was 15.1 +/- 4.2 (range 10-30) months for group A and 13.5 +/- 2.2 (range 12-20) months for group B. Remission occurred in 75.4% patients from group A and in 41.6% patients from group B (P less than 0.001). The mean follow-up was 42 +/- 14 months (17-81 months). The free T4 index (FT4I) in group A remained below the normal range during treatment. The mean FT4I, obtained during the course of treatment, of patients who went into remission from group A was significantly (P less than 0.001) lower than in relapsed patients (4.8 vs. 6.5). Moreover, there was an inverse correlation between mean FT4I and maintenance daily dose of either MMI (r = -0.567; P less than 0.001), or PTU (r = -0.379; P less than 0.01). A fall in microsomal antibody (MCHA) titer occurred mainly in remission patients, and was more significant (P less than 0.05) in group A patients. In contrast, 11 (7 from group B) of the 16 patients with an increase of microsomal antibody levels relapsed. The frequency of negative tests of thyroid-stimulating antibody was higher in group A patients (71%) than in group B (29%) at the end of therapy (P less than 0.01). No correlation was found between thyroid T3 suppressibility and either mean FT4I or thyroid-stimulatory antibody activity during treatment. Our findings show that patients treated with high doses of PTU or MMI throughout treatment have a higher remission rate when compared to those treated with a more conventional regimen. These results support the hypothesis that large antithyroid drug doses may have greater immunosuppressive effects than low dosage regimens. Furthermore, a high dosage regimen could permit the restoration of the immune surveillance mechanisms and, thus, lasting remission of Graves' disease.

Adolescent↗

[Low doses of insulin--comparison between hyperosmolar nonketotic coma and diabetic ketoacidosis (author's transl)].

The authors present a comparison between the results achieved in the treatment of 11 cases of nonketotic hyperosmolar "coma" and 13 cases of diabetic ketoacidosis using low doses of intramuscular insulin hourly. Surprisingly both, larger amounts of insulin and longer periods were needed to compensate the metabolic disturbance of the nonketotic hyperosmolar "coma" cases when compared to the ketoacidosis ones. The data obtained in this study suggest a possible direct relationship between the initial urea levels and the total amount of insulin needed to reduce the initial glycemia to a normal glycemic level.

Adult↗

[Glucose tolerance tests with oral glucose challenges of 50 and 100 grams (author's transl)].

Seventy six subjects (63 females and 13 males) with an average age of 50.5 years, all of them with familial and/or obstetric history for diabetes mellitus, were submitted to glucose tolerance tests with oral glucose challenges of 50 and 100 g. The tests were all analysed by different criteria of current usage in medical literature (Wilkerson, Fajans and Conn, British Diabetes Association and University Group Diabetes Program). We concluded that the 100 g glucose challenge gives a greater index of positivity by all the criteria above referred when compared to 50 g challenge. Wilkerson's criteria is less sensitive than the others, when applied to 100 g glucose challenges.

Administration, Oral↗